

Resource Summary Report

Generated by [RRID](#) on Jul 28, 2026

Brilliant Violet 605(TM) anti-human CD3

RRID:AB_2561911

Type: Antibody

Proper Citation

BioLegend Cat# 317322, RRID:AB_2561911

Antibody Information

URL: http://antibodyregistry.org/AB_2561911

Proper Citation: BioLegend Cat# 317322, RRID:AB_2561911

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 605(TM) anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone OKT3

Antibody ID: AB_2561911

Vendor: BioLegend

Catalog Number: 317322

Alternative Catalog Numbers: 317321

Record Creation Time: 20250819T220330+0000

Record Last Update: 20250820T005817+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 605(TM) anti-human CD3.

No alerts have been found for Brilliant Violet 605(TM) anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Shukla D, et al. (2025) CAR Binders Affect CAR T-cell Tonic Signaling, Durability, and Sensitivity to Target. Cancer immunology research, 13(6), 867.

Aznar MA, et al. (2025) Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer. Cell reports. Medicine, 6(9), 102301.

Webb L, et al. (2025) Membrane-bound IL-15 co-expression powers a potent and persistent CD70-targeted TRuC T-cell therapy. Frontiers in immunology, 16, 1609658.

Wagoner ZW, et al. (2025) Systems immunology analysis of human immune organoids identifies host-specific correlates of protection to different influenza vaccines. Cell stem cell, 32(4), 529.

Hamm F, et al. (2025) DNA methylomes undergo distinct waves of remodeling during thymic T cell development and do not acquire a proliferation-induced imprint. Cell reports, 44(8), 116092.

Quan A, et al. (2025) Antibody-gamma/delta T cell receptors targeting GPC2 regress neuroblastoma with low antigen density. Cell reports. Medicine, 102378.

Demetriou P, et al. (2025) CD2 costimulation strength: A key regulator of T cell function and anti-tumor immunity that is epigenetically regulated. iScience, 28(12), 113977.

Radziszewska A, et al. (2024) Type I interferon and mitochondrial dysfunction are associated with dysregulated cytotoxic CD8+ T cell responses in juvenile systemic lupus erythematosus. Clinical and experimental immunology.

Lim JME, et al. (2023) Protocol to detect antigen-specific nasal-resident T cells in humans. STAR protocols, 4(1), 101995.

Sims EK, et al. (2023) Inhibition of polyamine biosynthesis preserves β cell function in type 1 diabetes. Cell reports. Medicine, 4(11), 101261.

Kastenschmidt JM, et al. (2023) Influenza vaccine format mediates distinct cellular and antibody responses in human immune organoids. Immunity, 56(8), 1910.

Agarwal S, et al. (2023) Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. *Immunity*, 56(10), 2388.

Lim JME, et al. (2022) A comparative characterization of SARS-CoV-2-specific T cells induced by mRNA or inactive virus COVID-19 vaccines. *Cell reports. Medicine*, 3(11), 100793.

Khoo NKH, et al. (2022) Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients. *Med (New York, N.Y.)*, 3(2), 104.

Zaitsev A, et al. (2022) Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes. *Cancer cell*, 40(8), 879.

Lim JME, et al. (2022) SARS-CoV-2 breakthrough infection in vaccinees induces virus-specific nasal-resident CD8⁺ and CD4⁺ T cells of broad specificity. *The Journal of experimental medicine*, 219(10).

Kalimuddin S, et al. (2021) Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset. *Med (New York, N.Y.)*, 2(6), 682.

Good CR, et al. (2021) An NK-like CAR T cell transition in CAR T cell dysfunction. *Cell*, 184(25), 6081.

Richert-Spuhler LE, et al. (2021) CD101 genetic variants modify regulatory and conventional T cell phenotypes and functions. *Cell reports. Medicine*, 2(6), 100322.

Shuwa HA, et al. (2021) Alterations in T and B cell function persist in convalescent COVID-19 patients. *Med (New York, N.Y.)*, 2(6), 720.